naltrexone and Carcinoma, Ehrlich Tumor

naltrexone has been researched along with Carcinoma, Ehrlich Tumor in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abd Elmonem, FF; Abdel Rahman, MN; Aboalsoud, A; El-Ghaiesh, SH; Salem, ML	1

Other Studies

1 other study(ies) available for naltrexone and Carcinoma, Ehrlich Tumor

Article	Year
The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response. International immunopharmacology, 2020, Volume: 78 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Mice; Myeloid-Derived Suppressor Cells; Naltrexone; Off-Label Use; Proto-Oncogene Proteins c-bcl-2; Receptors, Opioid	2020

Article

Year

The effect of low-dose naltrexone on solid Ehrlich carcinoma in mice: The role of OGFr, BCL2, and immune response.

International immunopharmacology, 2020, Volume: 78

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Mice; Myeloid-Derived Suppressor Cells; Naltrexone; Off-Label Use; Proto-Oncogene Proteins c-bcl-2; Receptors, Opioid

2020